SCHEMBL44155

SCHEMBL44155

NC(Cc1cccc(C(F)(F)F)c1)C(=O)O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 2/20 0.64
HTR2C P28335 1/20 0.64
HTR2B P41595 1/20 0.64
GRB2 P62993 1/20 0.59
SLC7A5 Q01650 7/20 0.59
PTGS1 P23219 2/20 0.59
ALPI P09923 1/20 0.59
PKM P14618 1/20 0.59
XIAP P98170 1/20 0.59
GRIA2 P42262 1/20 0.56
NOS3 P29474 2/20 0.55
NOS1 P29475 2/20 0.55
NOS2 P35228 2/20 0.55
PPARG P37231 1/20 0.55
PPARA Q07869 1/20 0.55
EPHX1 P07099 1/20 0.54
DPP4 P27487 1/20 0.53
DPP8 Q6V1X1 1/20 0.53
DPP9 Q86TI2 1/20 0.53
DPP7 Q9UHL4 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29557134 1.00 HTR2A (0.64) HTR2AHTR2CHTR2BGRB2SLC7A5
SCHEMBL503602 1.00 HTR2A (0.64) HTR2AHTR2CHTR2BGRB2SLC7A5
SCHEMBL44156 1.00 HTR2A (0.64) HTR2AHTR2CHTR2BGRB2SLC7A5
SCHEMBL29478401 1.00 HTR2A (0.64) HTR2AHTR2CHTR2BGRB2SLC7A5
Hydrochloric Acid SCHEMBL10584250 0.98 HTR2A (0.62) HTR2AHTR2CHTR2BGRB2SLC7A5
Hydrochloric Acid SCHEMBL6775624 0.98 HTR2A (0.62) HTR2AHTR2CHTR2BGRB2SLC7A5
Hydrochloric Acid SCHEMBL6775619 0.98 HTR2A (0.62) HTR2AHTR2CHTR2BGRB2SLC7A5
SCHEMBL6831079 0.88 PPARG (0.60) HTR2AHTR2CHTR2BGRB2SLC7A5
SCHEMBL16131653 0.88 HTR2A (0.69) HTR2AHTR2CHTR2BEPHX1DPP4
SCHEMBL19943590 0.88 HTR2A (0.69) HTR2AHTR2CHTR2BEPHX1DPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1313 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120081924-A GLP-1R receptor agonistic polypeptide compounds and uses thereof 中国药科大学 2025-06-03 CN claimed
CN-119390784-A Dual-agonism polypeptide compound and medical application thereof 中国药科大学 2025-02-07 CN claimed
CN-118440155-B Dual-agonism polypeptide compound and medical application thereof 中国药科大学 2024-11-22 CN claimed
US-20240376044-A1 METHOD FOR PREPARING AROMATIC AMINO ACID DERIVATIVE CHUGAI PHARMACEUTICAL CO LTD (JP) 2024-11-14 US claimed
CN-118546214-A GLP-1R receptor agonistic polypeptide compounds and uses thereof 中国药科大学 2024-08-27 CN claimed
CN-118440155-A Dual-agonism polypeptide compound and medical application thereof 中国药科大学 2024-08-06 CN claimed
CN-105143245-B Anti-scaling material 耶路撒冷希伯来大学伊森姆研究发展有限公司 2021-02-05 CN claimed
EP-2951195-B1 ANTIFOULING MATERIALS YISSUM RES DEV CO OF HEBREW UNIV JERUSALEM LTD (IL) 2020-02-19 EP claimed
US-9631100-B2 Antifouling materials YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2017-04-25 US claimed
US-20150368480-A1 ANTIFOULING MATERIALS YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) 2015-12-24 US claimed
WO-2008031016-A2 HETEROCYCLIC LIGANDS FOR INTEGRIN IMAGING AND THERAPY THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2008-03-13 WO claimed
US-7053214-B2 β-sheet mimetics and composition and methods relating thereto MYRIAD GENETICS, INC. (US) 2006-05-30 US claimed
WO-2005122379-A9 ALPHA-4 BETA-1 INTEGRIN LIGANDS FOR IMAGING AND THERAPY UNIV CALIFORNIA (US) 2006-03-09 WO claimed
US-20060019900-A1 Alpha-4 beta-1 integrin ligands for imaging and therapy THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2006-01-26 US claimed
WO-2005122379-A2 ALPHA-4 BETA-1 INTEGRIN LIGANDS FOR IMAGING AND THERAPY THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2005-12-22 WO claimed
US-6943157-B2 Reverse-turn mimetics and composition and methods relating thereto MYRIAD GENETICS, INC. (US) 2005-09-13 US claimed
US-20020039749-A1 High-throughput screening assays for modulators of STAT4 and STAT6 activity AMGEN INC. 2002-04-04 US claimed
US-6207391-B1 INCUBATING A REACTION MIXTURE COMPRISING A STAT6 POLYPEPTIDE, A POTENTIAL BINDING MODULATOR, AND A RECEPTOR PEPTIDE WHICH COMPRISES A SPECIFIC AMINO ACID SEQUENCE TULARIK INC. 2001-03-27 US claimed
WO-1999050283-A1 HIGH THROUGHPUT SCREENING ASSAYS FOR MODULATORS OF STAT4 AND STAT6 ACTIVITY TULARIK INC. (US) 1999-10-07 WO claimed
US-5658885-A OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) 1997-08-19 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060019900-A1 Alpha-4 beta-1 integrin ligands for imaging and therapy ITGA4, ITGB4, ITGA1 HTR2A 3306/4885HTR2C 3517/4885HTR2B 1980/4885
US-20240376044-A1 METHOD FOR PREPARING AROMATIC AMINO ACID DERIVATIVE DDC, AADAT, TYR HTR2A 2278/4885HTR2C 2836/4885HTR2B 2599/4885
US-20150368480-A1 ANTIFOULING MATERIALS PFAS, FLNB, FLNA HTR2A 3133/4885HTR2C 3439/4885HTR2B 2881/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.